Products Affected - Description
Enalaprilat injection, Hospira
1.25 mg/mL, 1 mL vial, 1 count (NDC 00409-2122-01)
1.25 mg/mL, 2 mL vial, 1 count (NDC 00409-2122-02)
Enalaprilat injection, West-Ward
1.25 mg/mL, 1 mL vial, 10 count (NDC 00143-9787-10)
1.25 mg/mL, 2 mL vial, 10 count (NDC 00143-9786-10)
Reason for the Shortage
- Hospira has enalaprilat injection on shortage due to manufacturing delays.
- West-Ward has enalaprilat injection on shortage due to manufacturing delays.
There are no presentations available.
Estimated Resupply Dates
- Hospira has enalaprilat 1.25 mg/mL 1 mL and 2 mL vials on back order and the company estimates a release date of late-November 2015 for the 2 mL vials and early-December 2015 for the 1 mL vials.
- West-Ward has enalaprilat 1.25 mg/mL 1 mL and 2 mL vials on back order and the company estimates a release date of early-December 2015.
November 17, 2015, University of Utah, Drug Information Service. Copyright 2015, Drug Information Service, University of Utah, Salt Lake City, UT.
This information is provided through the support of Novation to ASHP solely as a service to its members, which shall not use this information for their further commercial use. The content was prepared by the Drug Information Center of University of Utah. Novation, ASHP, and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, which respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither Novation, ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this bulletin. Neither Novation, ASHP nor University of Utah endorses or recommends the use of any drug.
« Back to Drug Shortage Product Bulletins